logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

We Are Back

We Are Back! Thanks to God. Hello to all our subscribers. Our sickness was unanticipated, making our year start in February rather than January. We will tackle the sickness later in another article. Now it is time to appreciate and...

Read More

February 1, 2022

0

IVERIC Bio: Undeniable Promising News Today

IVERIC Bio ~ September 6, 2022 IVERIC bio ( ISEE ) announced positive results from GATHER2 second Phase 3 clinical trial of Zimura® (avacincaptad pegol) - a novel investigational complement C5 inhibitor for the treatment of geographic atrophy ( GA...

Read More

September 6, 2022

0

Sutro Biopharma Dosed the First Patient in the Dose-Expansion Cohort of the Phase 1 STRO-002 Study

Sutro Biopharma Therapeutic Discovery and Technology Sutro Biopharma ( STRO ) uses precise protein engineering and rational design for therapeutic discovery. The firm’s proprietary integrated cell-free protein synthesis platform known as XpressCF® and site-specific conjugation platform XpressCF+™ led to the...

Read More

January 21, 2021

0

Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for ALS

Amylyx Pharmaceuticals in the News Amylyx Pharmaceuticals ( AMLX ) : The U.S. FDA Peripheral and Central Nervous System Drugs Advisory Committee has voted (7 yes votes and 2 no votes) that the available evidence of effectiveness is sufficient to support approval of AMX0035...

Read More

September 8, 2022

0

Some Ideas About the Falling Stock Market Day

The Stock Market Today Before the end of 2021 we recognized that investors were not going to swallow what was reiterated about the strong economy. The fact was there were no criteria for a strong economy. Instead, the unparalleled inflation...

Read More

February 3, 2022

0

Akero Therapeutics: Efruxifermin Met Primary Endpoint for Both Dose Groups in NASH Patients

Akero Therapeutics Akero Therapeutics ( AKRO ) - a clinical-stage company, today released topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin ( EFX ) in patients with pre-cirrhotic...

Read More

September 13, 2022

0

Intellia Therapeutics: Excellent News from NTLA-2001 Phase 1 Clinical Trial

Intellia Therapeutics  Intellia Therapeutics.( NTLA ) and  Regeneron Pharmaceuticals ( REGN ) today announced positive interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (...

Read More

September 16, 2022

0

ViiV Healthcare: The FDA Approved Cabenuva for Adults Who are HIV Virologically-Suppressed

ViiV Healthcare Announced FDA Approval for Cabenuva for Adults with HIV-1 From London we learned that ViiV Healthcare announced that the US Food and Drug Administration ( FDA ) approved Cabenuva, the first and only complete long-acting regimen for the...

Read More

January 25, 2021

0

From Biogen and Eisai: Lecanemab Confirmatory Phase 3 Clarity Met Primary Endpoint for Early Alzheimer’s Disease  

Biogen & Eisai Co and Early Alzheimer's Disease  From Tokyo and Cambridge, Eisai Co., Ltd. and Biogen Inc. ( BIIB ) announced positive topline results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab. The product...

Read More

September 28, 2022

0

CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab's Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma

CASI Pharmaceuticals Partner, BioInvent International, Announced Positive Interim Results for NHL CASI Pharmaceuticals ( CASI ) partner BioInvent International ( BINV ) announced positive interim results from the Phase I/IIa trial of the novel anti-FcγRIIB product BI-1206 when combined with...

Read More

January 28, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 130
  • 131
  • 132
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy